Alumis says it is on track to submit Envudeucitinib NDA in 4Q
Alumis said it is on track to submit an NDA for Envudeucitinib in moderate-to-severe plaque psoriasis in 4Q.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.